Sarepta Therapeutics (NASDAQ:SRPT) had its price target decreased by Needham & Company LLC from $196.00 to $170.00 in a research report report published on Wednesday, The Fly reports. Needham & Company LLC currently has a buy rating on the biotechnology company’s stock.

A number of other equities analysts have also issued reports on SRPT. Piper Jaffray Companies reduced their target price on Sarepta Therapeutics from $208.00 to $185.00 and set an overweight rating for the company in a research note on Tuesday, August 20th. Credit Suisse Group reduced their target price on Sarepta Therapeutics from $207.00 to $201.00 and set an outperform rating for the company in a research note on Tuesday, August 20th. Robert W. Baird reduced their target price on Sarepta Therapeutics from $202.00 to $181.00 and set an outperform rating for the company in a research note on Tuesday, August 20th. Evercore ISI restated a buy rating and issued a $200.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, August 8th. Finally, Cantor Fitzgerald reduced their target price on Sarepta Therapeutics from $231.00 to $175.00 and set an overweight rating for the company in a research note on Tuesday, August 20th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and twenty-one have issued a buy rating to the company. The company has an average rating of Buy and a consensus target price of $197.78.

Shares of SRPT stock opened at $93.61 on Wednesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 7.84 and a current ratio of 8.81. The business has a fifty day moving average of $139.42 and a 200 day moving average of $130.16. Sarepta Therapeutics has a 1 year low of $90.24 and a 1 year high of $165.87.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($3.74) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.08) by ($2.66). The firm had revenue of $94.67 million during the quarter, compared to analysts’ expectations of $91.05 million. Sarepta Therapeutics had a negative return on equity of 55.37% and a negative net margin of 165.52%. The business’s revenue was up 28.8% on a year-over-year basis. During the same quarter last year, the business earned ($1.67) EPS. Equities research analysts anticipate that Sarepta Therapeutics will post -3.21 EPS for the current year.

In related news, CEO Douglas S. Ingram purchased 16,252 shares of the business’s stock in a transaction on Monday, August 12th. The shares were bought at an average cost of $123.07 per share, with a total value of $2,000,133.64. Following the transaction, the chief executive officer now owns 424,405 shares of the company’s stock, valued at $52,231,523.35. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Richard Barry purchased 3,700 shares of the business’s stock in a transaction on Wednesday, August 14th. The shares were bought at an average cost of $122.50 per share, for a total transaction of $453,250.00. Following the completion of the transaction, the director now directly owns 3,177,065 shares in the company, valued at approximately $389,190,462.50. The disclosure for this purchase can be found here. Insiders have acquired a total of 26,252 shares of company stock worth $3,109,234 over the last ninety days. 6.60% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the company. Evolution Wealth Advisors LLC acquired a new stake in shares of Sarepta Therapeutics during the 2nd quarter valued at about $25,000. Trust Co. of Vermont grew its position in shares of Sarepta Therapeutics by 2,125.0% during the 2nd quarter. Trust Co. of Vermont now owns 178 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 170 shares during the period. Steward Partners Investment Advisory LLC acquired a new stake in shares of Sarepta Therapeutics during the 2nd quarter valued at about $32,000. Lindbrook Capital LLC acquired a new stake in shares of Sarepta Therapeutics during the 1st quarter valued at about $35,000. Finally, BSW Wealth Partners acquired a new stake in shares of Sarepta Therapeutics during the 2nd quarter valued at about $52,000. Hedge funds and other institutional investors own 93.59% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Featured Article: Initial Public Offering (IPO)

The Fly

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.